Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9340481 | Supportive Cancer Therapy | 2005 | 11 Pages |
Abstract
Given the high rate of febrile neutropenia in cycle 1 and the higher risk for subsequent events in patients with a cycle 1 event, we conclude that growth factor administration starting in cycle 1 should be considered for patients receiving moderately to highly myelosuppressive chemotherapy regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jeffrey Crawford, John A. Glaspy, Ronald G. Stoller, Dianne K. Tomita, Martha E. Vincent, Brian W. McGuire, Howard Ozer,